EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 4.2

ph-index = 1

Location History:

Hattersheim, DE (2007 - 2012)
Kelkeim, DE (2012)
Kelkheim, DE (2009 - 2013)
Frankfurt-am-Main, DE (2011 - 2016)

Company Filing History:

8 out of 1,827

Sanofi-a Ventis Deutschland Gmbh

Years Active: 2007-2016

where 'Filed Patents' based on already Granted Patents

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9346762 - Pyrazole derivatives and their use as LPAR5 antagonists (2016-05-24),

2. 9346757 - Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation (2016-05-24),

3. 9221784 - Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists (2015-12-29),

4. 8420321 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism (2013-04-16),

5. 8329167 - EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases (2012-12-11),

6. 8211427 - EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases (2012-07-03),

7. 8198022 - Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof (2012-06-12),

8. 8114398 - EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart disease (2012-02-14),

9. 8084198 - Use of a GIP promoter polymorphism (2011-12-27),

10. 8071297 - Method for the diagnosis and treatment of cardiovascular diseases (2011-12-06),

11. 7985562 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism (2011-07-26),

12. 7892744 - Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders (2011-02-22),

13. 7888020 - Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof (2011-02-15),

14. 7785781 - Method of diagnosis of a predisposition to develop thrombotic disease and its uses (2010-08-31),

15. 7560290 - Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism (2009-07-14),

Certainly! Here is an article about inventor Detlef Kozian:

Title: A Glimpse into the Innovative Mind of Detlef Kozian

Introduction:

Detlef Kozian, a prolific inventor based in Frankfurt am Main, DE, has made significant contributions to the field of pharmacology with numerous patented inventions. With a keen focus on developing compounds for the treatment of cardiovascular disorders, Kozian's work continues to pave the way for advancements in modern medicine.

Latest Patents:

1. Pyridine derivatives for the treatment of conditions associated with pathological thrombus formation: Kozian's latest patent introduces compounds of formula (I) that serve as effective antagonists of the platelet LPA receptor LPAR5. These compounds show promise in treating various disorders, including thromboembolic diseases and restenoses. Additionally, the patent covers processes for compound preparation and their use in pharmaceutical compositions.

2. Pyrazole derivatives as LPAR5 antagonists: Another groundbreaking patent by Kozian showcases compounds of formula (I) with potent antagonistic properties against the platelet LPA receptor LPAR5. These compounds offer potential therapeutic benefits for cardiovascular disorders and other conditions involving LPA receptor activation. The patent also includes methods for compound synthesis and their application in medicaments.

Career Highlights:

Detlef Kozian has demonstrated exceptional expertise during his tenure at companies like Sanofi-Aventis Deutschland GmbH and Sanofi. His innovative approach to drug development and research has led to the successful patenting of 16 inventions, highlighting his profound impact on the pharmaceutical industry.

Collaborations:

Throughout his career, Kozian has collaborated with esteemed professionals in the field, including notable coworkers such as Jean-Francois Deleuze and Sylvain Ricard. These collaborations have fostered a dynamic environment for idea exchange and innovation, further enhancing Kozian's inventive capabilities.

Conclusion:

Detlef Kozian's inventive spirit and dedication to advancing pharmacological research have positioned him as a leading figure in the development of novel compounds for cardiovascular therapies. His patented inventions not only reflect his ingenuity but also signify a promising future for the treatment of complex medical conditions. As Kozian continues to push the boundaries of scientific discovery, his contributions are set to leave a lasting legacy in the realm of innovative pharmacology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

7 patents (EPO):

Please report any incorrect information to support@idiyas.com

4 patents pending (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.